Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signaling Lymphocyte Activation Molecule F7 (SLAMF7)
- Target
- SLAMF7
- Molecular classification
- Type I transmembrane glycoprotein, Receptor, Signaling Lymphocytic Activation Molecule (SLAM) family
01
Overview
SLAMF7 (Signaling Lymphocyte Activation Molecule F7), also known as CD319, CS1, or CRACC, is a type I transmembrane protein belonging to the SLAM family of receptors. It is primarily expressed on immune cells such as NK cells, T cells, B cells, and plasma cells, and functions as a self-ligand receptor mediating homophilic interactions. SLAMF7 plays a crucial role in immune modulation, promoting NK cell cytotoxicity, regulating B cell activity and adaptive immunity, and influencing macrophage activation during inflammation. It is a diagnostic and therapeutic target for plasma cell malignancies, particularly multiple myeloma, due to its robust expression on malignant plasma cells.
- Other names
- CD319CS1CRACC
02
Mechanism of action
Modulation of immune cell activity via homophilic interactions and downstream signaling through EAT-2 or SAP adaptors; promotion of NK cell cytotoxicity and degranulation.
03
Biological functions
Immune modulationNK cell cytotoxicity/degranulationB cell activity regulationAdaptive immunity regulationCell signalingPhagocytosis
04
Disease associations
Multiple myelomaAutoimmunitySepsisCancer
05
Biomarkers
SLAMF7 expression level in plasma cells (diagnostic/prognostic in multiple myeloma)
Beyond the preview
Go deeper on Signaling Lymphocyte Activation Molecule F7 (SLAMF7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Signaling Lymphocyte Activation Molecule F7 (SLAMF7).